Lazard Asset Management
MPLT

Lazard Asset Management’s MapLight Therapeutics MPLT Stock Holding History

Lazard Asset Management’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.87M Sell
80,082
-61,934
-44% -$1.78M ﹤0.01% 815
2026
Q1 		$2.89M Sell
142,016
-65,478
-32% -$1.17M ﹤0.01% 748
2025
Q4 		$3.64M Buy
+207,494
New +$3.48M 0.01% 656

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Lazard Asset Management's MPLT Position: Q2 2026 in Review

Lazard Asset Management reduced its MapLight Therapeutics (MPLT) stake by 44% in Q2 2026, selling an estimated $1.78M and leaving 80,082 shares worth $2.87M. The position accounts for ﹤0.01% of the portfolio, ranked #815.

Lazard Asset Management first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.64M in Q4 2025. 100 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Lazard Asset Management held 80,082 shares of MapLight Therapeutics worth $2.87M as of Q2 2026.
  • Lazard Asset Management sold 61,934 MapLight Therapeutics shares in Q2 2026, an estimated $1.78M.
  • MapLight Therapeutics made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #815 holding.
  • Lazard Asset Management first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Lazard Asset Management's MapLight Therapeutics position peaked at $3.64M in Q4 2025.
  • 100 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.